Polydexa ear drops solution bottle 10.5 ml

Pharmacodynamic parameters. The combination of active pharmaceutical ingredients of the drug Polydex determines its anti-inflammatory and antimicrobial effects against a wide range of gram-positive and gram-negative pathogens of infectious-inflammatory diseases of the external ear.

Synthetic GCS dexamethasone penetrates the cell membrane and binds with high affinity to specific cytoplasmic glucocorticoid receptors, which ultimately leads to modification of transcription and, consequently, protein synthesis to achieve inhibition of leukocyte infiltration at the site of inflammation, interference with the function of inflammatory mediators, suppression of humoral immune reactions and reduction of edema. The anti-inflammatory effect of dexamethasone involves phospholipase A _2- inhibiting proteins lipocortins, which control the biosynthesis of such potent inflammatory mediators as prostaglandins and leukotrienes.

Neomycin is an aminoglycoside antibiotic isolated from cultures of Streptomyces fradiae. Its mechanism of action involves inhibition of protein synthesis essential for microbial cell growth by binding to the 30S subunit of the bacterial ribosome. Neomycin may also inhibit bacterial DNA polymerase.

Neomycin is active against B. catarrhalis and Haemophilus influenzae, Acinetobacter, Corynebacterium, Listeria pathogens, Methicillin-resistant Staphylococcus, bacteria of the genera Citrobacter, Enterobacter, Campylobacter, Escherichia coli, Klebsiella, Morganella, Proteus, Providencia, Serratia, Salmonella, Shigella, Yersinia, and Pasteurella.

Neomycin-resistant enterococci, streptococci, methicillin-resistant staphylococci, chlamydia, mycoplasma, rickettsia, P. stuartii, Pseudomonas aeruginosa, A. denitrificans, Burkholderia, N. asteroides, flavobacteria, S. maltophilia, resistant anaerobic microorganisms.

Polymyxin B, a lipopeptide antibiotic isolated from Bacillus polymyxa, has a bactericidal effect on gram-negative bacteria: α- and γ-diaminobutyric acids of positively charged polymyxin B form electrostatic interactions with phosphate groups of negatively charged lipid A on the outer membrane of gram-negative bacteria. Calcium and magnesium ions are displaced from the phosphates of membrane lipids, destabilizing lipopolysaccharide, which increases membrane permeability and, as a result, leads to cell destruction. In addition, polymyxin B inhibits NADH-quinone oxidoreductase type II on the inner bacterial membrane, which is necessary for cellular respiration, and can also bind and neutralize lipopolysaccharide released during bacterial lysis, preventing the endotoxin response.

Acinetobacteria, Aeromonas, Alcaligenes spp., Microorganisms of the genera Citrobacter, Enterobacteria, Escherichia coli, Klebsiella, Moraxella, Pseudomonas aeruginosa, Salmonella, Shigella, S. maltophilia are sensitive to polymyxin B.

Resistance to polymyxin B is demonstrated by Brucella, Burkholderia (B. cepacia, B. pseudomallei), mycobacteria, B. catarrhalis, campylobacter, legionella, morganella, protea, neisseria, serratia, providencia, C. meningosepticum, Vibrio cholerae biovar El Tor, spherical and rod-shaped spore-forming bacteria.

Pharmacokinetic parameters. In the case of an intact eardrum, there is no absorption into the systemic bloodstream.

Topical therapy of external otitis of bacterial etiology in the absence of damage to the eardrum (including eczema of the external auditory canal of an infectious nature).

Locally (burying in the external auditory canal) 2 times a day – morning and evening.

Adults 1-5 drops, children 1-2 drops (depending on age).

The duration of the course of therapy (on average 1 week) is individual and is determined by the severity of the pathology and its nature.

Before use, warm the bottle in your hands to body temperature. Tilt your head (and keep it in this position for another 5 minutes after instillation); instill the drug into the external auditory canal without pressure, then slightly pull the earlobe back (repeat several times).

After the end of the course of therapy, dispose of the bottle, do not reuse.

Hypersensitivity to the active pharmaceutical ingredients or other components of the drug;

the presence (or suspicion of the presence) of a violation of the integrity of the eardrum;

infectious process of the external auditory canal of viral etiology (including chickenpox and herpes simplex).

Before starting therapy, an examination of the eardrum is required.

The solution is not administered orally or by injection.

During therapy, it is necessary to follow approved guidelines for the proper use of antibacterial agents.

The presence of corticosteroids in the drug may affect the symptoms of an allergic reaction.

In case of an allergic reaction, the use of the drug should be discontinued immediately.

Dexamethasone in the drug may cause a positive reaction to a doping test.

To minimize the likelihood of microbial contamination, it is necessary to prevent contact of the skin of the hand or ear with the edge of the dropper.

If symptoms persist after 10 days of therapy, a repeat medical consultation is necessary.

With prolonged therapy or use of doses of the drug exceeding the recommended ones, the development of systemic effects is possible.

Use during pregnancy and breastfeeding is possible after a careful assessment of the benefit to the mother over the possible risk to the fetus/child.

There are no age restrictions for children.

Does not affect the ability to drive vehicles or operate other mechanisms.

Concomitant use with any other topical medications is undesirable.

Not found.

Keep out of reach of children, at a temperature ≤25 °C.